Disclosures for "Neurosarcoidosis Management in Pregnancy: A Review and Longitudinal Case Study"
-
An immediate family member of Dr. Patel has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Patel has stock in Ocular Therapeutix. Dr. Patel has stock in Autolus Therapeutics . Dr. Patel has stock in Larimar Therapeutics. Dr. Patel has stock in Viking Therapeutics. An immediate family member of Dr. Patel has stock in Voyager Therapeutics. An immediate family member of Dr. Patel has stock in BridgeBio Pharma, Inc.. An immediate family member of Dr. Patel has stock in Stoke Therapeutics. The institution of an immediate family member of Dr. Patel has received research support from The Patient-Centered Outcomes Research Institute.
-
Dr. Esch has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Esch has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Esch has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Esch has received research support from PCORI.